Tecan and TAP Biosystems Announces a Co-Marketing Agreement
News Nov 01, 2012
Tecan and TAP Biosystems have announced a co-marketing agreement to further expand the automated 3D cell culture capabilities of the Freedom EVO® liquid handling platform.
Automation of TAP’s collagen-based RAFT™ cell culture system will allow scientists to quickly and conveniently create 3D cell cultures in a 96-well, SBS-format.
The RAFT 3D cell culture system uses biologically relevant concentrations of collagen matrix to ensure cells grow and proliferate in an environment closely resembling the native tissue.
The Freedom EVO workstation is configured with a number of modules, including reagent and microplate cooling units and a heated shaking device, to provide fully automated preparation and maintenance of RAFT cell cultures.
This ensures rapid, reliable creation of consistent and reproducible 3D cell cultures, offering walkaway processing for a wide range of cell biology applications.
Kevin Moore, Head of Applications and Solutions at Tecan, commented: “We are pleased to further expand our automated 3D cell culture portfolio to include the RAFT system. Working together with TAP Biosystems, we will be able to offer a complete solution for automated 3D cell culture.”
Dr Grant Cameron, TAP Biosystems’ RAFT Development Director, added: “RAFT is rapidly becoming a core secondary screening technology within drug discovery. This exciting collaboration will enable researchers to expand the power of the realistic collagen environment of RAFT, with substantially increased throughput to meet their cell-based screening requirements.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE